Shafay Raheel1, Eric L Matteson1,2, Cynthia S Crowson1,3, Elena Myasoedova1. 1. Division of Rheumatology, Department of Internal Medicine. 2. Division of Epidemiology, Department of Health Sciences Research. 3. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Abstract
Objective: To assess trends in the occurrence of flares and remission in RA over recent decades. Methods: A retrospective medical records review of each clinical visit was performed in a population-based cohort of patients with RA (age ⩾30 years; 1987 ACR criteria met in 1988-2007) to estimate flare and remission status. RA flare was defined as any worsening of RA activity leading to an initiation, change or increase of therapy (OMERACT 9). The primary definition for remission required the absence of RA disease activity (i.e. tender joint count 0, swollen joint count 0 and ESR ⩽10 mm/h) (OMERACT 7). All subjects were followed until death, migration or 1 July 2012. Results: The study included 650 RA patients (mean age 55.8 years; 69% female) with a mean follow up of 10.3 years. Patients were flaring at 2887 (17%) visits. There was a significant decline in the RA flare rate across disease duration (P < 0.001), predominantly in the first 5 years after diagnosis of RA. Patients diagnosed with RA in more recent years experienced fewer flares during first few years of RA (P < 0.001). There was no difference between the sexes in trends of flare rates over time (P = 0.42) Current smokers had higher flare rates than non-smokers (P = 0.047) and former smokers were not different from non-smokers (P = 0.87). Conclusion: Patients diagnosed in more recent years have lower flare rates than those diagnosed in prior decades. Flare rates declined fastest in the first 5 years of disease and tended to be stable thereafter. Current smoking was associated with an adverse flare profile.
Objective: To assess trends in the occurrence of flares and remission in RA over recent decades. Methods: A retrospective medical records review of each clinical visit was performed in a population-based cohort of patients with RA (age ⩾30 years; 1987 ACR criteria met in 1988-2007) to estimate flare and remission status. RA flare was defined as any worsening of RA activity leading to an initiation, change or increase of therapy (OMERACT 9). The primary definition for remission required the absence of RA disease activity (i.e. tender joint count 0, swollen joint count 0 and ESR ⩽10 mm/h) (OMERACT 7). All subjects were followed until death, migration or 1 July 2012. Results: The study included 650 RApatients (mean age 55.8 years; 69% female) with a mean follow up of 10.3 years. Patients were flaring at 2887 (17%) visits. There was a significant decline in the RA flare rate across disease duration (P < 0.001), predominantly in the first 5 years after diagnosis of RA. Patients diagnosed with RA in more recent years experienced fewer flares during first few years of RA (P < 0.001). There was no difference between the sexes in trends of flare rates over time (P = 0.42) Current smokers had higher flare rates than non-smokers (P = 0.047) and former smokers were not different from non-smokers (P = 0.87). Conclusion:Patients diagnosed in more recent years have lower flare rates than those diagnosed in prior decades. Flare rates declined fastest in the first 5 years of disease and tended to be stable thereafter. Current smoking was associated with an adverse flare profile.
Authors: Yang Liu; Glen S Hazlewood; Gilaad G Kaplan; Bertus Eksteen; Cheryl Barnabe Journal: Arthritis Care Res (Hoboken) Date: 2016-12-31 Impact factor: 4.794
Authors: Elena Myasoedova; Cynthia S Crowson; Carl Turesson; Sherine E Gabriel; Eric L Matteson Journal: J Rheumatol Date: 2011-04-01 Impact factor: 4.666
Authors: Keeranur Jayakumar; Sam Norton; Josh Dixey; David James; Andrew Gough; Peter Williams; Peter Prouse; Adam Young Journal: Rheumatology (Oxford) Date: 2011-11-16 Impact factor: 7.580
Authors: E Tanaka; A Mannalithara; E Inoue; M Hara; T Tomatsu; N Kamatani; G Singh; H Yamanaka Journal: Ann Rheum Dis Date: 2007-10-30 Impact factor: 19.103
Authors: Rieke Alten; Christof Pohl; Ernest H Choy; Robin Christensen; Daniel E Furst; Sarah E Hewlett; Amye Leong; James E May; Tessa C Sanderson; Vibeke Strand; Thasia G Woodworth; Clifton O Bingham Journal: J Rheumatol Date: 2011-08 Impact factor: 4.666
Authors: Iris M Markusse; Linda Dirven; Andreas H Gerards; Johannes H L M van Groenendael; H Karel Ronday; Pit J S M Kerstens; Willem F Lems; Tom W J Huizinga; Cornelia F Allaart Journal: Arthritis Res Ther Date: 2015-08-31 Impact factor: 5.156
Authors: Elena Myasoedova; John M Davis; Vanessa L Kronzer; Rachel E Giblon; Elizabeth J Atkinson; Nathan K LeBrasseur; Cynthia S Crowson Journal: Semin Arthritis Rheum Date: 2021-12-31 Impact factor: 5.431
Authors: Irina A Tikhonova; Huiqin Yang; Segun Bello; Andrew Salmon; Sophie Robinson; Mohsen Rezaei Hemami; Sophie Dodman; Andriy Kharechko; Richard C Haigh; Meghna Jani; Timothy J McDonald; Martin Hoyle Journal: Health Technol Assess Date: 2021-02 Impact factor: 4.014
Authors: Navraj S Nagra; Danielle E Robinson; Ian Douglas; Antonella Delmestri; Stephanie G Dakin; Sarah J B Snelling; Andrew J Carr; Daniel Prieto-Alhambra Journal: Sci Rep Date: 2019-06-20 Impact factor: 4.379